NexLife vs Gimme Care
All-in cost at every dose, fee structure, care model, pharmacy disclosure and terms — compared on one basis.
Only NexLife publishes a price we could capture ($2,580 for a first year at a maintenance dose). The other does not, so this comparison cannot be settled on cost.
What can be compared is what each discloses: visit model, pharmacy identity, laboratory requirement and cancellation terms. Those are below.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
NexLife vs Gimme Care at every dose
A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.
NexLife against Gimme Care at every dose
| Dose | NexLife | Gimme Care | Cheaper |
|---|---|---|---|
| 2.5 mg | $215 | — | — |
| 5 mg | $215 | — | — |
| 7.5 mg | $215 | — | — |
| 10 mg | $215 | — | — |
| 12.5 mg | $215 | — | — |
| 15 mg | $215 | — | — |
What differs beyond price
Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.
| Attribute | NexLife | Gimme Care |
|---|---|---|
| Pricing model | flat at every dose | model unknown |
| Membership | none | none |
| Prepaid rate | $186 | none published |
| Visit model | async | not published |
| Labs | not required | not published |
| Pharmacy disclosure | 6 named partners | not published |
| Cancellation | cancel any time on monthly | not published |
| Regulatory status | compounded, not FDA-approved | compounded, not FDA-approved |
| Evidence status | ✓ verified at source | no price published |
Which one, for whom
If you want the lowest total cost: neither can be ranked on cost until both publish a price.
If you want budget certainty: NexLife, which holds one price at every strength.
If you want to verify the supply chain: NexLife, which names its dispensing pharmacy.
If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.
Switching between them
Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.
Fee structure, side by side
NexLife charges no recurring fee on top of medication. Gimme Care charges no recurring fee.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
NexLife: async, labs not required, 1:1 call included. Gimme Care: visit model not published, labs not published, coaching not published.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
NexLife: 6 named partners. Gimme Care: pharmacy not disclosed.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
What can still be decided here
Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.
NexLife publishes: visit model async, laboratory requirement not required, pharmacy 6 named partners, cancellation cancel any time on monthly. Gimme Care publishes: visit model not stated, laboratory requirement not stated, pharmacy not stated, cancellation not stated.
A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.
Putting nexlife and gimme care in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting any one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 17 programmes publish a price we could capture, spanning $215 to $548 a month all-in at a maintenance dose. Against a spread that wide, most optimisation attempted at the margins is worth less than getting the basis right once.
What good looks like
A programme that states a figure at a named dose, names the pharmacy behind it, publishes cancellation terms before payment, and says plainly that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority of the market does all four.
The cheapest verified route sits at $215 a month all-in, which establishes that disclosure and low price are not in tension. Programmes publishing more are not systematically dearer — which undercuts the usual explanation for withholding.
What to do next
Narrow to two or three on the criterion that actually binds for you, open the individual reviews, and send each the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel, and what is refundable.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
Why this comparison cannot be settled on price
Only NexLife publishes a price we could capture, at about $2,580 for a first year at a maintenance dose. The other does not. A comparison that filled that gap with an estimate would be inventing the only number that matters.
What can be compared is what each discloses before you pay, and that is frequently the more useful comparison anyway. A programme that names its pharmacy, states its cancellation terms and publishes a price at every dose has told you how it will behave when something goes wrong.
What to do instead
Ask both for the total at 10 mg including every fee, in writing, and compare the replies against the programmes that already publish. If one answers in a sentence and the other does not answer at all, you have your comparison.
Why we publish the page anyway
Because the absence is the finding. Someone searching for this pairing deserves to know that one side cannot be priced, rather than being shown a fabricated number or no page at all.
Fee structure, side by side
NexLife charges no recurring fee on top of medication. Gimme Care charges no recurring fee.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
NexLife: async, labs not required, 1:1 call included. Gimme Care: visit model not published, labs not published, coaching not published.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
NexLife: 6 named partners. Gimme Care: pharmacy not disclosed.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
What can still be decided here
Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.
NexLife publishes: visit model async, laboratory requirement not required, pharmacy 6 named partners, cancellation cancel any time on monthly. Gimme Care publishes: visit model not stated, laboratory requirement not stated, pharmacy not stated, cancellation not stated.
A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.
Putting nexlife and gimme care in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting any one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 17 programmes publish a price we could capture, spanning $215 to $548 a month all-in at a maintenance dose. Against a spread that wide, most optimisation attempted at the margins is worth less than getting the basis right once.
What good looks like
A programme that states a figure at a named dose, names the pharmacy behind it, publishes cancellation terms before payment, and says plainly that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority of the market does all four.
The cheapest verified route sits at $215 a month all-in, which establishes that disclosure and low price are not in tension. Programmes publishing more are not systematically dearer — which undercuts the usual explanation for withholding.
What to do next
Narrow to two or three on the criterion that actually binds for you, open the individual reviews, and send each the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel, and what is refundable.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Is NexLife or Gimme Care cheaper?
Only one of the two publishes a price we could capture, so this comparison cannot be settled on cost. Both are compared on terms and disclosure instead.
Do NexLife and Gimme Care charge a membership on top of medication?
NexLife: no. Gimme Care: no. Every figure on this page includes it where charged.
Does NexLife or Gimme Care name its dispensing pharmacy?
NexLife: 6 named partners. Gimme Care: not published. It is the disclosure that lets you check a state board register before you inject anything weekly.
Can I switch between them mid-treatment?
Usually yes, after a clinical review. Confirm dose continuity in writing and do not cancel the old programme until the new one has shipped, because a supply gap costs more than a price difference.
Is either NexLife or Gimme Care FDA-approved?
Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Where a programme supplies brand product, that product is approved; the programme around it is not a regulated entity in the same sense.